Insulinoma treatment primarily involves the surgical removal of the tumor, which is usually curative. For those who cannot undergo surgery, medications like diazoxide or octreotide may be used to manage symptoms. Dietary adjustments, such as frequent small meals, are also recommended to control hypoglycemia.

Insulinoma Treatment Market Overview

Global Insulinoma Treatment Market reached US$ YY million in 2023 and is expected to reach US$ YY  million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Insulinomas are rare pancreatic endocrine tumors, with only about 10% being malignant. These tumors cause hypoglycemia by oversecreting insulin, leading to dangerously low blood sugar levels. Most insulinomas are benign, and the primary treatment is surgery. For cases where surgery isn't possible, somatostatin analogs like octreotide and lanreotide are used to reduce insulin secretion by the pancreatic islet cells. Approximately 5-12% of insulinomas are metastatic, and when they spread to lymph nodes or the liver, the survival rate is typically around two years.

Request for free sample:https://www.datamintelligence.com/download-sample/insulinoma-treatment-market

Insulinoma Treatment Market Growth

The incidence of neuroendocrine tumors (NETs), including insulinomas, has been on the rise globally in recent decades, particularly in the gastrointestinal tract, pancreas, and bronchial regions. Insulinomas, a type of NET that causes excessive insulin secretion and hypoglycemia, have seen a notable increase in prevalence over the past two years. These tumors are often linked to environmental factors that lead to gene mutations.

Insulinoma occurs at a rate of 1 to 4 cases per million people annually, with the majority being single, benign tumors. However, about 5.8% of insulinomas can be malignant. Surgery is highly effective, with over 87.5% of patients experiencing a cure, defined as being symptom-free for at least six months post-operation. Insulinomas predominantly affect individuals between the ages of 30 and 60, with women accounting for approximately 59% of cases.

Get your customized report @https://www.datamintelligence.com/customize/insulinoma-treatment-market

The Insulinoma Treatment Market is segmented 

By Disease Type:  Benign, Metastatic

By Treatment Type:  Chemotherapy (Anti cytotoxic drugs (Doxorubicin, Fluorouracil, Etoposide, Others), Somatostatin Analogues (Octreotide, Lanreotide), Radiation Therapy (Stereotactic ablation radiation therapy (SABR), Selective internal radiation therapy (SIRT)), Surgeries, Others

By End User:  Hospitals and Clinics, Cancer Research Centers and Institutes, Others

By Region:  North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Insulinoma Treatment Market Companies

• Baxter International Inc.   
• Salvavidas
• AdvaCare Pharma
• Merck KGaA
• Accord Healthcare US
• Midas Pharma GmbH
• Biosynth
• Livealth
• Ipsen Biopharmaceuticals, Inc.
• Cipla USA, Inc.

Related Reports

Insomnia Treatment Market

Cholesteatoma Treatment Market

Type 2 Diabetes Market

Contact Us:

Company Name: DataM Intelligence

Email: info@datamintelligence.com

Contact Person: Sai. K

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About DataM Intelligence:

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. At DataM Intelligence, we leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across